Your browser doesn't support javascript.
loading
Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang, Zhengguang; Guo, Yuanyuan; Chen, Meijuan; Chen, Feiyan; Liu, Bing; Shen, Cunsi.
Afiliación
  • Zhang Z; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China. zhengguangzhang@njucm.edu.cn.
  • Guo Y; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Chen M; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Chen F; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Liu B; School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Shen C; Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210023, China. cunsishen@126.com.
Inflammopharmacology ; 29(5): 1587-1601, 2021 Oct.
Article en En | MEDLINE | ID: mdl-34322786

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Quempferoles / Inhibidores de Proteínas Quinasas / Clorhidrato de Erlotinib Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Inflammopharmacology Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Quempferoles / Inhibidores de Proteínas Quinasas / Clorhidrato de Erlotinib Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Inflammopharmacology Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza